Nektar Therapeutics (NKTR) Reports Q4 Loss of $0.21

Nektar Therapeutics (NASDAQ: NKTR) reported Q4 EPS of ($0.21), versus ($0.28) reported last year. Revenue for the quarter came in at $95.5 million, versus $37.5 million reported last year.

For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.

You May Also Be Interested In

• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
• S&P 500 may pull back before midterms, but Citi says buy the dip
• Ubiquiti (UI) Tops Q4 EPS by 25c, Beats on Revenue